Wednesday, July 8, 2026

pharma · SH2B1 Deficiency Obesity · Prader-Willi Syndrome · SLNO

SOLENO THERAPEUTICS

SOLENO THERAPEUTICS clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Redwood City, USA HQ
199 Employees
Public company Type
SLNO · NYSE Ticker
Company details
Status
Public
HQ
Redwood City, USA
Employees
199
Programs
2
Drugs
4
Patents
0
Intelligence · Clinical Programs

SOLENO THERAPEUTICS projects

1 ClinicalTrials.gov programs sponsored by SOLENO THERAPEUTICS.

SOLENO THERAPEUTICS has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. DCCR

    SOLENO THERAPEUTICS INC

    Prader-Willi Syndrome

    phase 3 small molecule active

    4 trials

Frequently asked questions

How many clinical projects does SOLENO THERAPEUTICS have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.